Liquid Biopsy Approach in Precision Oncology

dc.contributor.advisorKurg, Ants
dc.contributor.authorRuiz Acosta, Alberto
dc.date.accessioned2021-05-27T10:45:56Z
dc.date.available2021-05-27T10:45:56Z
dc.date.issued2020
dc.description.abstractLiquid biopsy serves as a tool to analyse cell-free nucleic acids (cfNAs) and circulating tu-mour cells (CTCs) in blood or other body fluids in individuals with cancer. These are con-sidered promising diagnostic and prognostic biomarkers but new discoveries are still being made in regard to their heterogeneity, therefore it is critical to continue researching to demonstrate a clinical advantage in precision oncology. For now they promise to reveal mo-lecular characterisation of tumours which can change the prognosis, monitoring and post-therapy of cancer care. This is challenging because the technologies and methodologies are still not mature enough for capturing and isolating viable cells. Higher affinity and sensitive techniques including a combination of these may result in an efficient characterisation of CTCs and cfNAs. From pre-treatment of blood samples to post-analysis of isolated markers it is required to standardize and regulate methods in order to prove clinical utility, as of now this remains in the experimental phase. Microfluidic systems have become an influential tool in cancer studies for their capability to analyse single cells or molecules and its integration with other techniques, miniaturization and fast analysis which will help overcome challenges these biomarkers face to eventually replace traditional biopsy with liquid biopsy. In estonian: Bakalaureusetöö on kirjutatud inglise keeles, kirjanduse põhjal ning on klassikalise ülesehi-tusega koosnedes sissejuhatusest, kirjanduse ülevaatest, töö eesmärkidest, diskussioonist ja kokkuvõttest. Töö on esitatud 40-l leheküljel, sisaldades ka ühe joonise ja neli tabelit. Töö koostamisel on kasutatud 48 kirjanduse allikat. Töö põhisisuks on ülevaate andmine erinevatest vedelbiopsia meetoditest, mille abil saab vähi patsientidel analüüsida veres või muudes kehavedelikes ringlevaid rakuvabasid nuk-leiinhappeid (cfNAd) ja ringlevaid vähirakke (CTCd). Neid peetakse paljutõotavateks diag-nostilisteks ja prognostilisteks biomarkeriteks, mis võimaldavad senisest paremini ning mitte-invasiivselt iseloomustada kasvajaid molekulaarsel tasemel. See on väga oluline vähi patsientide personaalses ravis, võimaldades kasvajate tekke ja arengu paremat jälgimist ning ravi. Töös on kirjeldatud cfNA-de ja CTC-de olemust, päritolu, eraldamist ning analüüsiks kasutatavaid tehnoloogiaid. Samuti on võrreldud vedelbiopsia kasutatavust ja perspektiive tänapäeval traditsiooniliselt rakendatava klassikalise biopsia meetoditega. Arutelu osas on antud ülevaade meetodite hetkeseisust ja võimalikest arengutest tulevikus.en
dc.identifier.urihttp://hdl.handle.net/10062/72083
dc.language.isoenget
dc.rightsopenAccesset
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectLiquid biopsyen
dc.subjectcancer diagnosisen
dc.subjectcirculating tumour cellsen
dc.subjectcirculating cell-free nucleic acidsen
dc.subjectVedelbiopsiaet
dc.subjectvähidiagnooset
dc.subjectveres ringlevad vähirakudet
dc.subjectveres ringlev rakuvaba DNAet
dc.titleLiquid Biopsy Approach in Precision Oncologyen
dc.title.alternativeVedelbiopsia meetodid onkoloogiaset
dc.typeinfo:eu-repo/semantics/bachelorThesiset

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
RuizAcosta_BSc2020.pdf
Size:
961.59 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.67 KB
Format:
Item-specific license agreed upon to submission
Description: